BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 36056434)

  • 1. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
    Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
    J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
    Arisi MF; Dotan E; Fernandez SV
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA.
    Frydendahl A; Rasmussen MH; Jensen SØ; Henriksen TV; Demuth C; Diekema M; Ditzel HJ; Wen SWC; Pedersen JS; Dyrskjøt L; Andersen CL
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.
    Sogbe M; Bilbao I; Marchese FP; Zazpe J; De Vito A; Pozuelo M; D'Avola D; Iñarrairaegui M; Berasain C; Arechederra M; Argemi J; Sangro B
    Clin Mol Hepatol; 2024 Apr; 30(2):177-190. PubMed ID: 38163441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors.
    Lenaerts L; Vandenberghe P; Brison N; Che H; Neofytou M; Verheecke M; Leemans L; Maggen C; Dewaele B; Dehaspe L; Vanderschueren S; Dierickx D; Vandecaveye V; Amant F; Vermeesch JR
    Ann Oncol; 2019 Jan; 30(1):85-95. PubMed ID: 30371735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
    Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
    Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer.
    Kim MH; Kim GM; Ahn JM; Ryu WJ; Kim SG; Kim JH; Kim TY; Han HJ; Kim JY; Park HS; Park S; Park BW; Kim SI; Jeong J; Lee J; Paik S; Kim S; Jung KH; Cho EH; Sohn J
    J Natl Cancer Inst; 2023 Sep; 115(9):1036-1049. PubMed ID: 37166557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
    Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
    Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 11. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays.
    Szász I; Kiss T; Mokánszki A; Koroknai V; Deák J; Patel V; Jámbor K; Ádány R; Balázs M
    Mol Cell Probes; 2023 Feb; 67():101888. PubMed ID: 36513244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
    Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R
    Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Enzymatically Converted Cell-Free DNA (cfDNA) Data for Copy Number Variation-Linked Fragmentation Analysis Allows for Early Colorectal Cancer Detection.
    Černoša I; Trincado-Alonso F; Canal-Noguer P; Kruusmaa K; Perera-Lluna A
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis - an update.
    Molnár B; Galamb O; Kalmár A; Barták BK; Nagy ZB; Tóth K; Tulassay Z; Igaz P; Dank M
    Expert Rev Mol Diagn; 2019 Jun; 19(6):477-498. PubMed ID: 31046485
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection.
    Kim SY; Jeong S; Lee W; Jeon Y; Kim YJ; Park S; Lee D; Go D; Song SH; Lee S; Woo HG; Yoon JK; Park YS; Kim YT; Lee SH; Kim KH; Lim Y; Kim JS; Kim HP; Bang D; Kim TY
    Exp Mol Med; 2023 Nov; 55(11):2445-2460. PubMed ID: 37907748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
    Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
    Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
    Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
    Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder.
    Lee DH; Yoon H; Park S; Kim JS; Ahn YH; Kwon K; Lee D; Kim KH
    Sci Rep; 2018 Oct; 8(1):14707. PubMed ID: 30279572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing.
    Ge G; Peng D; Guan B; Zhou Y; Gong Y; Shi Y; Hao X; Xu Z; Qi J; Lu H; Zhang X; Zhan Y; Li Y; Wu Y; Ding G; Shen Q; He Q; Li X; Zhou L; Ci W
    Clin Chem; 2020 Jan; 66(1):188-198. PubMed ID: 31811000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.